CDSCO declares 59 drugs tested in August as Not of Standard Quality
The Central Drugs Standard Control Organisation (CDSCO) recently released a troubling report revealing that 59 drug samples were declared Not of Standard Quality (NSQ) in August 2024. This list includes samples from well-known manufacturers, raising serious concerns about the integrity of pharmaceutical products available in the market. As the healthcare community and patients await clarity, it’s essential to understand the implications of this report. The NSQ Report: Key Findings According to the CDSCO, 48 NSQ samples were reported directly by the organization, while state regulators contributed 11 additional samples. Notable failures included: Clavam 625 (amoxicillin and potassium clavulanate tablets) from Alkem Health Science. Pan-D (pantoprazole gastro-resistant and domperidone prolonged-release capsules) also from Alkem Health Science. Cepodem XP50 (cefpodoxime proxetil and potassium clavulanate) from Hetero Labs Ltd. Paracetamol tablets and metronidazole tablets from pu...